JPJimyung Park

Jimyung Park

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jimyung Park has a total of 108 co-authors. Here are the top co-authors by number of shared publications:

  • Sun Mi Choi

    Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea

    5 shared publications
  • Jong Hyuk Lee

    Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea

    4 shared publications
  • Jong Hyuk Lee

    Department of Radiology, Seoul National University Hospital, Seoul, Korea

    4 shared publications
  • Sun Mi Choi

    Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea

    4 shared publications
  • Hong Yeul Lee

    Department of Critical Care Medicine, Seoul National University Hospital, Seoul, Republic of Korea

    3 shared publications
  • Jae-Joon Yim

    Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea

    3 shared publications

Latest Publications

  • Open Access

    Deep learning–based quantification of CT changes after 1 year of pirfenidone treatment as a prognostic marker in idiopathic pulmonary fibrosis

    by Ji Young Lee, Kum Ju Chae, Myoung-Jin Jang, Jonathan H. Chung, Jin Mo Goo, Sun Mi Choi, Jimyung Park, Jong Hyuk Lee

    Objectives: To evaluate the prognostic value of changes in deep learning–based CT quantification following 1 year of pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF). Materials and methods: This study included patients with IPF who received at least 1 year of pirfenidone between September 2009 and March 2022 at two hospitals. The extent of normal lung and fibrosis (sum of reticular opacity and honeycombing) was quantified on baseline and 1-year follow-up chest CT scans using a deep learning–based tool, and the changes were calculated. The primary outcome was a composite of all-cause mortality or lung transplantation; the secondary outcome was a ≥ 10% absolute decline in forced vital capacity (FVC) occurring after the 1-year follow-up. Associations between changes in CT quantification and these outcomes were assessed using Cox proportional hazards regression analyses. Results: A total of 436 patients (341 men; mean age, 69.8 years) were included. Greater preservation of normal lung extent over 1 year was associated with a lower risk of the composite outcome (adjusted hazard ratio (HR) per 5% increase: 0.90; 95% confidence interval (CI): 0.85, 0.96; p < 0.001), whereas increases in fibrosis extent were associated with a higher risk (adjusted HR per 5% increase: 1.16, 95% CI: 1.06, 1.27, p = 0.002). Regarding the secondary outcome of ≥ 10% absolute FVC decline, only the change in fibrosis extent remained a significant predictor (adjusted HR per 5% increase: 1.26, 95% CI: 1.09, 1.45, p = 0.001). Conclusions: Changes in deep learning–based CT quantification results over 1 year of pirfenidone treatment demonstrated significant prognostic value in patients with IPF. Key Points: Question Disease progression and mortality in patients with idiopathic pulmonary fibrosis (IPF) continue to occur unpredictably beyond 1 year of pirfenidone treatment. Findings Changes in deep learning–based quantification of normal lung and fibrosis extent after 1 year of pirfenidone treatment were significant prognostic predictors. Critical relevance statement Incorporating 1-year changes in deep learning–based CT quantification improves prognostication of mortality, lung transplantation, and lung function decline, supporting more individualized risk stratification in idiopathic pulmonary fibrosis.

  • Progression and mortality of Mycobacterium abscessus complex pulmonary disease

    by Seonghye Jung, Juye Bae, Joong-Yub Kim, Jimyung Park, Nakwon Kwak, Jinwoo Lee, Taek Soo Kim, Moon-Woo Seong, Yunhee Choi, Jae-Joon Yim

  • Open Access

    Functional, Volumetric, and Growth Outcomes After Pediatric Bilateral Lung Transplantation

    by Seon Yong Bae, Samina Park, Dae Hyeon Kim, Taeyoung Yun, Ji Hyeon Park, Bubse Na, Kwon Joong Na, Hyun Joo Lee, Ji Soo Park, Dong In Suh, et al.

    Objective: Long‐term multidimensional evaluations of pediatric lung transplantation are limited. This study assessed the functional recovery, volumetric adaptation, and growth in pediatric recipients by comparing age and graft type. Methods: This single‐center, retrospective, descriptive study longitudinally reviewed 16 children (age < 18 years) who underwent bilateral deceased‐donor lung transplantation. Perioperative characteristics, pulmonary function, computed tomography (CT)–derived lung volume, somatic growth, and survival were analyzed. Overall survival (OS) and chronic lung allograft dysfunction (CLAD)–free survival were estimated using the Kaplan–Meier method, and longitudinal physiological and developmental patterns were assessed descriptively. Results: In the younger group (≤ 10 years, n = 7) and the older group (> 10 years, n = 9), lobar transplantation was performed in 5 (71.4%) and 3 (33.3%) patients, respectively. CLAD was diagnosed in 1 younger recipient (14.3%) and 2 older recipients (22.2%). OS did not differ significantly between age groups (log‐rank p = 0.96), and CLAD‐free survival was comparable (log‐rank p = 0.73). CT volumetry demonstrated progressive postoperative lung expansion with similar temporal trajectories across age groups and between lobar and whole‐lung grafts. Growth patterns demonstrated meaningful postoperative improvement, with many children who exhibited faltering pretransplant growth demonstrating catch‐up toward individualized percentile curves. Conclusions: Pediatric lung transplantation results in favorable long‐term recovery, including functional improvement, durable volumetric adaptation, and partial restoration of growth dynamics. Comparable outcomes between lobar and whole‐lung grafts support the use of size‐reduced grafts in cases of donor–recipient mismatch.

  • Open Access

    Impact of race-neutral GLI reference equations in Northeast Asian patients with IPF.

    by Hyeonsu Lee, Chang-Hoon Lee, Kwonhyung Hyung, Sun Mi Choi, Sang-Min Lee, Jimyung Park

    The Global Lung Function Initiative (GLI) has recently introduced race-neutral reference equations for pulmonary function tests, replacing traditional ethnic-specific equations. However, the clinical impact of this transition in Northeast Asian patients with idiopathic pulmonary fibrosis (IPF) remains unclear. We evaluated the implications of switching from the ethnic-specific equations to the race-neutral GLI equations in 903 Korean patients newly diagnosed with IPF between 2005 and 2020. Per cent predicted values of forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO) were calculated using both equations and used to derive the baseline gender-age-physiology (GAP) index scores. We then compared the prognostic performance of GAP staging derived from each equation in predicting all-cause mortality. Additionally, we assessed the clinical impacts of 1-year absolute declines in FVC and DLCO % predicted, as determined by each equation. The race-neutral GLI equations yielded higher FVC % predicted and lower DLCO % predicted values compared with the ethnic-specific equations, resulting in GAP stage reclassification in 203 of 903 patients (22.5%), predominantly toward lower stages. Despite these differences, the agreement in GAP staging between the two equations was substantial (Cohen's kappa 0.628) and their predictive performance for mortality did not significantly differ (C-index 0.686 vs 0.684; p=0.598). One-year absolute declines in FVC and DLCO % predicted were similarly associated with increased mortality, regardless of reference equation used. In Northeast Asian patients with IPF, race-neutral GLI equations resulted in reclassification of GAP stage for some patients but did not affect the overall prognostic performance of the GAP index in predicting mortality.

  • Prognostic impact of low muscle mass on clinical outcomes in patients who undergo lung transplant

    by Hyun-Jun Park, Sun Mi Choi, Kwon Joong Na, Samina Park, Hyun Joo Lee, Young Tae Kim, Woo Hyeon Lim, Soon Ho Yoon, Jong Hyuk Lee, Jimyung Park


  • Open Access

    Connective tissue disease is associated with the risk of posterior reversible encephalopathy syndrome following lung transplantation in Korea

    by Tae Jung Kim, Hyun Joo Lee, Samina Park, Sang-Bae Ko, Soo-Hyun Park, Seung Hwan Yoon, Kwon Joong Na, In Kyu Park, Chang Hyun Kang, Young Tae Kim, et al.

    Background: Posterior reversible encephalopathy syndrome (PRES) is a rare complication of lung transplantation with poorly understood risk factors and clinical characteristics. This study aimed to examine the occurrence, risk factors, and clinical data of patients who developed PRES following lung transplantation.Methods: A retrospective analysis was conducted on 147 patients who underwent lung transplantation between February 2013 and December 2023. The patients were diagnosed with PRES based on the clinical symptoms and radiological findings. We compared the baseline characteristics and clinical information, including primary lung diseases and immunosuppressive therapy related to lung transplantation operations, between the PRES and non-PRES groups.Results: PRES manifested in 7.5% (n=11) of the patients who underwent lung transplantation, with a median onset of 15 days after operation. Seizures were identified as the predominant clinical manifestation (81.8%, n=9) in the group diagnosed with PRES. All patients diagnosed with PRES recovered fully. Patients with PRES were significantly associated with connective tissue disease-associated interstitial lung disease (45.5% vs. 18.4%, P=0.019, odds ratio=9.808; 95% CI, 1.064–90.386; P=0.044). Nonetheless, no significant variance was observed in the type of immunotherapy, such as the use of calcineurin inhibitors, blood pressure, or acute renal failure subsequent to lung transplantation.Conclusions: PRES typically manifests shortly after lung transplantation, with seizures being the predominant initial symptom. The presence of preexisting connective tissue disease as the primary lung disease represents a significant risk factor for PRES following lung transplantation.


  • Open Access

    Prognostic implication of 1-year decline in diffusing capacity in newly diagnosed idiopathic pulmonary fibrosis

    by Hyeonsu Lee, So Yeon Kim, Young Sik Park, Sun Mi Choi, Jong Hyuk Lee, Jimyung Park

    The progression of idiopathic pulmonary fibrosis (IPF) is assessed through serial monitoring of forced vital capacity (FVC). Currently, data regarding the clinical significance of longitudinal changes in diffusing capacity for carbon monoxide (DLCO) is lacking. We investigated the prognostic implications of a 1-year decline in DLCO in 319 patients newly diagnosed with IPF at a tertiary hospital between January 2010 and December 2020. Changes in FVC and DLCO over the first year after the initial diagnosis were reviewed; a decline in FVC ≥ 5% and DLCO ≥ 10% predicted were considered significant changes. During the first year after diagnosis, a significant decline in FVC and DLCO was observed in 101 (31.7%) and 64 (20.1%) patients, respectively. Multivariable analysis showed that a 1-year decline in FVC ≥ 5% predicted (aHR 2.74, 95% CI 1.88–4.00) and 1-year decline in DLCO ≥ 10% predicted (aHR 2.31, 95% CI 1.47–3.62) were independently associated with a higher risk of subsequent mortality. The prognostic impact of a decline in DLCO remained significant regardless of changes in FVC, presence of emphysema, or radiographic indications of pulmonary hypertension. Therefore, serial monitoring of DLCO should be recommended because it may offer additional prognostic information compared with monitoring of FVC alone.


  • Measurement Variability of Same-Day CT Quantification of Interstitial Lung Disease: A Multicenter Prospective Study

    by Jong Hyuk Lee, Kum Ju Chae, Jimyung Park, Sun Mi Choi, Myoung-Jin Jang, Eui Jin Hwang, Gong Yong Jin, Jin Mo Goo

    Purpose To investigate quantitative CT (QCT) measurement variability in interstitial lung disease (ILD) on the basis of two same-day CT scans. Materials and Methods Participants with ILD were enrolled in this multicenter prospective study between March and October 2022. Participants underwent two same-day CT scans at an interval of a few minutes. Deep learning-based texture analysis software was used to segment ILD features. Fibrosis extent was defined as the sum of reticular opacity and honeycombing cysts. Measurement variability between scans was assessed with Bland-Altman analyses for absolute and relative differences with 95% limits of agreement (LOA). The contribution of fibrosis extent to variability was analyzed using a multivariable linear mixed-effects model while adjusting for lung volume. Eight readers assessed ILD fibrosis stability with and without QCT information for 30 randomly selected samples. Results Sixty-five participants were enrolled in this study (mean age, 68.7 years ± 10 [SD]; 47 [72%] men, 18 [28%] women). Between two same-day CT scans, the 95% LOA for the mean absolute and relative differences of quantitative fibrosis extent were -0.9% to 1.0% and -14.8% to 16.1%, respectively. However, these variabilities increased to 95% LOA of -11.3% to 3.9% and -123.1% to 18.4% between CT scans with different reconstruction parameters. Multivariable analysis showed that absolute differences were not associated with the baseline extent of fibrosis (P = .09), but the relative differences were negatively associated (β = -0.252, P < .001). The QCT results increased readers' specificity in interpreting ILD fibrosis stability (91.7% vs 94.6%, P = .02). Conclusion The absolute QCT measurement variability of fibrosis extent in ILD was 1% in same-day CT scans. Keywords: CT, CT-Quantitative, Thorax, Lung, Lung Diseases, Interstitial, Pulmonary Fibrosis, Diagnosis, Computer Assisted, Diagnostic Imaging Supplemental material is available for this article. © RSNA, 2024.


  • Open Access

    Association between body fat decrease during the first year after diagnosis and the prognosis of idiopathic pulmonary fibrosis: CT-based body composition analysis

    by Ji Young Lee, Soon Ho Yoon, Jin Mo Goo, Jimyung Park, Jong Hyuk Lee

    The prognostic role of changes in body fat in patients with idiopathic pulmonary fibrosis (IPF) remains underexplored. We investigated the association between changes in body fat during the first year post-diagnosis and outcomes in patients with IPF. This single-center, retrospective study included IPF patients with chest CT scan and pulmonary function test (PFT) at diagnosis and a one-year follow-up between January 2010 and December 2020. The fat area (cm2, sum of subcutaneous and visceral fat) and muscle area (cm2) at the T12-L1 level were obtained from chest CT images using a fully automatic deep learning-based software. Changes in the body composition were dichotomized using thresholds dividing the lowest quartile and others, respectively (fat area: -52.3 cm2, muscle area: -7.4 cm2). Multivariable Cox regression analyses adjusted for PFT result and IPF extent on CT images and the log-rank test were performed to assess the association between the fat area change during the first year post-diagnosis and the composite outcome of death or lung transplantation. In total, 307 IPF patients (69.3 ± 8.1 years; 238 men) were included. During the first year post-diagnosis, fat area, muscle area, and body mass index (BMI) changed by -15.4 cm2, -1 cm2, and − 0.4 kg/m2, respectively. During a median follow-up of 47 months, 146 patients had the composite outcome (47.6%). In Cox regression analyses, a change in the fat area < -52.3 cm2 was associated with composite outcome incidence in models adjusted with baseline clinical variables (hazard ratio [HR], 1.566, P = .022; HR, 1.503, P = .036 in a model including gender, age, and physiology [GAP] index). This prognostic value was consistent when adjusted with one-year changes in clinical variables (HR, 1.495; P = .030). However, the change in BMI during the first year was not a significant prognostic factor (P = .941). Patients with a change in fat area exceeding this threshold experienced the composite outcome more frequently than their counterparts (58.4% vs. 43.9%; P = .007). A ≥ 52.3 cm2 decrease in fat area, automatically measured using deep learning technique, at T12-L1 in one year post-diagnosis was an independent poor prognostic factor in IPF patients.


  • Pulse versus non‐pulse corticosteroid therapy in patients with acute exacerbation of idiopathic pulmonary fibrosis

    by Kwonhyung Hyung, Jong Hyuk Lee, Joong‐Yub Kim, Sun Mi Choi, Jimyung Park

    Background and Objective: Corticosteroids are commonly used for the treatment of acute exacerbation of idiopathic pulmonary fibrosis (AE‐IPF); however, the optimal initial dose of corticosteroids remains uncertain due to a lack of sufficient evidence. We evaluated whether the administration of a pulse dose of corticosteroids resulted in improved survival outcomes compared with conventional non‐pulse dose of corticosteroids.Methods: We retrospectively analysed 238 patients with AE‐IPF treated with corticosteroids at a tertiary referral hospital between January 2013 and December 2021. Based on whether a pulse dose of corticosteroids (methylprednisolone of ≥250 mg/day or equivalent) was administered within 7 days of hospitalization for AE‐IPF, the patients were divided into the pulse and non‐pulse regimen groups. The survival outcomes were compared between the two groups using multivariable regression and propensity score‐matched analyses.Results: Among the 238 patients, 59 patients received pulse dose of corticosteroids, whereas 179 patients received conventional non‐pulse dose of corticosteroids. After adjusting for the confounding factors related to the baseline clinical and radiographic severity, compared with the conventional non‐pulse regimen, the pulse regimen of corticosteroids did not reduce the risk of mortality at the 3‐month (aHR 0.84, 95% CI 0.45–1.38) or 12‐month (aHR 0.96, 95% CI 0.60–1.25) follow‐ups. Propensity score‐matched analysis revealed similar results.Conclusion: The survival outcomes of patients with AE‐IPF who received a pulse dose of corticosteroids did not differ from those of patients who received conventional non‐pulse dose of corticosteroids. Further prospective studies are required to establish the optimal initial dose of corticosteroids for the treatment of AE‐IPF.